Prandin, Novonorm(repaglinide)
NovoNorm, Prandimet, Prandin (repaglinide) is a small molecule pharmaceutical. Repaglinide was first approved as Prandin on 1997-12-22. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against ATP-binding cassette sub-family C member 8.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| prandin | New Drug Application | 2017-12-28 |
| repaglinide | ANDA | 2023-04-04 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| type 2 diabetes mellitus | EFO_0001360 | D003924 | E11 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BD: Combinations of oral blood glucose lowering drugs
— A10BD14: Metformin and repaglinide
— A10BX: Other blood glucose lowering drugs, excl. insulins in atc
— A10BX02: Repaglinide
HCPCS
No data
Clinical
Clinical Trials
55 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 3 | 1 | 2 | 18 | 7 | 31 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | 2 | 1 | — | 3 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | — | 2 | — | 1 | 3 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 9 | — | — | — | — | 9 | ||
| Neoplasms | D009369 | C80 | 2 | — | — | — | — | 2 | |
| Drug interactions | D004347 | 2 | — | — | — | — | 2 | ||
| Mitochondrial diseases | D028361 | EFO_0000591 | 1 | — | — | — | — | 1 | |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | — | — | — | — | 1 |
| Prostatic neoplasms | D011471 | C61 | 1 | — | — | — | — | 1 | |
| Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | 1 | — | — | — | — | 1 |
| Mantle-cell lymphoma | D020522 | C83.1 | 1 | — | — | — | — | 1 | |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | 1 | — | — | — | — | 1 | |
| Malaria | D008288 | EFO_0001068 | B54 | 1 | — | — | — | — | 1 |
Show 1 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | REPAGLINIDE |
| INN | repaglinide |
| Description | Repaglinide is a member of piperidines. |
| Classification | Small molecule |
| Drug class | antidiabetic, sodium glucose co-transporter 2 (SGLT2) inhibitors, not phlorozin derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 135062-02-1 |
| RxCUI | 73044 |
| ChEMBL ID | CHEMBL1272 |
| ChEBI ID | 8805 |
| PubChem CID | 65981 |
| DrugBank | DB00912 |
| UNII ID | 668Z8C33LU (ChemIDplus, GSRS) |
Target
Agency Approved
ABCC8
ABCC8
Organism
Homo sapiens
Gene name
ABCC8
Gene synonyms
HRINS, SUR, SUR1
NCBI Gene ID
Protein name
ATP-binding cassette sub-family C member 8
Protein synonyms
ATP-binding cassette transporter sub-family C member 8, ATP-binding cassette, sub-family C (CFTR/MRP), member 8, sulfonylurea receptor (hyperinsulinemia), Sulfonylurea receptor 1
Uniprot ID
Mouse ortholog
Abcc8 (20927)
ATP-binding cassette sub-family C member 8 (B2RUS7)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,122 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more